"The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems".

Luzum JA1,2, Pakyz RE3, Elsey AR4, Haidar CE5, Peterson JF6,7, Whirl-Carrillo M8, Handelman SK2, Palmer K3, Pulley JM9, Beller M10, Schildcrout JS11, Field JR9, Weitzel KW4, Cooper-DeHoff RM4, Cavallari LH4, O'Donnell PH12, Altman RB8, Pereira N13, Ratain MJ12, Roden DM6, Embi PJ14, Sadee W2,15, Klein TE8, Johnson JA4, Relling MV5, Wang L16, Weinshilboum RM16, Shuldiner AR3, Freimuth RR17; Pharmacogenomics Research Network Translational Pharmacogenetics Program.

Author information

Abstract

Numerous pharmacogenetic clinical guidelines and recommendations have been published, but barriers have hindered the clinical implementation of pharmacogenetics. The Translational Pharmacogenetics Program (TPP) of the NIH Pharmacogenomics Research Network was established in 2011 to catalog and contribute to the development of pharmacogenetic implementations at eight US healthcare systems, with the goal to disseminate real-world solutions for the barriers to clinical pharmacogenetic implementation. The TPP collected and normalized pharmacogenetic implementation metrics through June 2015, including gene-drug pairs implemented, interpretations of alleles and diplotypes, numbers of tests performed and actionable results, and workflow diagrams. TPP participant institutions developed diverse solutions to overcome many barriers, but the use of Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines provided some consistency among the institutions. The TPP also collected some pharmacogenetic implementation outcomes (scientific, educational, financial, and informatics), which may inform healthcare systems seeking to implement their own pharmacogenetic testing programs. This article is protected by copyright. All rights reserved.